Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsAlnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology CongressAugust 30, 20242024 Fall NewsletterSeptember 25, 20242024 Winter NewsletterJanuary 18, 2024 Previous post2026 Winter NewsletterNext postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis
